Dr George Mukhari Hospital (previously Ga-Rankuwa Hospital) is a tertiary level academic hospital in the Gauteng Province and bordering on the Limpopo and North West Provinces in South Africa. From 700 through 900 children with diarrhea were admitted to the pediatric wards annually (23%-25 % of total admissions), with a mortality of 8% during 2000-2004 (Department of Paediatrics and Child Health, Medunsa/GaRankuwa Hospital, unpublished data). During 2003, preliminary research found that, of 952 diarrheal stool specimens, 165 (17%) were positive for rotavirus. The incidence of rotavirus infection was highest during the cool, dry winter months, peaking at 56% during May (the start of the South African winter) (J Dewar, personal communication).
The high disease burden associated with rotavirus infection has emphasized the need to develop rotavirus vaccines to reduce acute rotavirus diarrhea and subsequent risk of hospitalizations. In 2005, 2 candidate vaccines were licensed in the United States, and by October 2007, the vaccines were licensed in 1160 countries [12] , including South Africa in July 2006 [13] .
A recently completed double-blind, placebo-controlled, phase II trial conducted in a peri-urban and rural area adjacent to Dr George Mukhari Hospital showed that a live attenuated oral human rotavirus vaccine (RIX4414) could be successfully coadministered with poliovirus vaccines as part of the Extended Program of Immunization (EPI) schedule [14] . In September 2008, after being available only in the private sector, the vaccine was introduced as part of the EPI in a rural area in the Eastern Cape, South Africa [15] .
A major consequence of rotavirus disease in young children is the need for medical and parental care, clinic visits, hospitalization, and loss of work by the parents. Notwithstanding the data on mortality and morbidity associated with diarrheal disease, to date, there is no information concerning the costs associated with the burden of diarrheal disease in South Africa. Although a rotavirus vaccine will reduce the morbidity and mortality associated with diarrheal disease, its introduction and sustainability will incur considerable costs. Thus, to determine the cost benefit of introducing the vaccine, the economic cost of diarrheal disease to the country must be known.
This study was undertaken as part of a global study coordinated by the World Health Organization (WHO) to determine the economic burden of diarrheal disease. The specific objectives were to estimate the costs associated with diarrheal disease of all etiologies in children !5 years of age admitted as inpatients to Dr George Mukhari Hospital and to compare costs for the management of rotaviral diarrhea with those of diarrhea due to other pathogens. Associated costs were identified as (1) direct medical costs (medications, laboratory tests, diagnostics, personnel, and overheads), (2) direct nonmedical costs (travel and other out-of-pocket costs incurred by the household as a result of the child having diarrhea), and (3) indirect costs (time lost from productive work by the parent or caregiver).
METHODS
A standard protocol specifying the data required, providing example questionnaires and record forms, and giving guidelines for sample size calculation and data collection and analysis was provided by the WHO (U Griffiths, R Rheingans, D Walker, unpublished data). The standard protocol, however, allowed local sites to adapt it to their own circumstances.
Study design. The study design comprised 2 arms: a review of the medical records of patients !5 years of age admitted to the hospital for diarrheal disease during 2004 and a prospective arm involving the recording of all expenses incurred during the hospital stays of children with diarrheal disease during the peak rotavirus season (March-July) in 2005.
Ethics. The study was approved by the Chief Executive Officer of Dr George Mukhari Hospital and the Research, Ethics, and Publications Committee of the Faculty of Medicine of the University of Limpopo (Medunsa campus). All selected caregivers for the prospective arm of the study were provided with a detailed explanation of the study before obtainment of written informed consent.
Sample size and selection. During 2003, 780 patients !5 years of age were admitted to the medical pediatric wards of Dr George Mukhari Hospital for diarrheal disease (Department of Paediatrics and Child Health, Medunsa/Ga-Rankuwa Hospital, unpublished data). With a 0.5 coefficient of variation for treatment cost data and 10% level of precision, the desired sample size was 85 patient records (U Griffiths, R Rheingans, D Walker, unpublished data). Calculating a 40% margin for incomplete or unavailable records for the record review arm, the desired sample size was set at 120 patient records. To have comparable data for 2005, the prospective arm aimed to enroll 85 patients.
The patient database of the Department of Pediatrics and Child Health was used to identify patients admitted for diarrheal disease during 2004. The sample was stratified according to month of admission and whether diarrheal disease was the only diagnosis or whether there were comorbidities. Records of patients who were infected with HIV were excluded. Systematic sampling was used to select the records to be included in the sample. For the prospective enrollment arm, all patients in the age group !5 years admitted to the pediatrics admission ward during March-June 2005, who were not HIV infected, and whose caregivers were available and willing to participate were recruited into the study.
Data collection. Selected patient records were drawn from the Hospital Records Department and were reviewed for use of resources by a research assistant. The following resource utilization data were abstracted from the records: visits to clinic, casualty, or outpatient department immediately before admission; admission and discharge dates; ward; type, frequency, amount, duration, and route of administration of oral rehydration solution, intravenous fluids, and all medications, including discharge medications directly related to the diarrheal episode; laboratory tests and diagnostic procedures ordered; and review appointments booked and kept. All data abstraction forms were cross-checked by the principal investigator for accuracy and completeness.
Eligible patients were identified by the research assistant at admission. The patients' records were reviewed, and data abstraction forms were updated daily until discharge. Caregivers were interviewed in their language of preference with use of a standardized interview schedule as soon after admission as possible. Questions were asked regarding transportation, consultations before the hospital visit, medicines bought, expenses incurred during the hospitalization, and losses of wages resulting from absence from work. Data analysis. All data on the abstraction forms and interview schedules were entered in Excel (Microsoft) spreadsheets before the calculation of costs. For consistency, prices for the 2004-2005 financial year were used to calculate costs. All cost calculations were done by entering the appropriate formulae in the Excel spreadsheets. Cost calculations were as follows:
• Direct medical cost p facility cost + professional cost + diagnostic cost + medication cost + nondrug order cost.
• Household costs p transport cost + previous treatment costs + incidental costs.
• Indirect costs p wages lost.
The components of the above costs were calculated as follows:
• Facility cost p (number of days in hospital [including the day of admission and the day of discharge]) ϫ cost of a general pediatric bed-day) + (number of pediatrics outpatient department or casualty visits ϫ cost of outpatient or casualty visit) [16] .
• Professional cost p (number of outpatient or casualty consultations ϫ cost of general medical practitioner consultation) + (cost of specialist consultation + [number of hospital days ϫ cost of general medical practitioner consultation]) [16] . It was assumed that inpatients were seen once during their hospital stay by a specialist pediatrician and daily by a general medical practitioner.
• Diagnostic cost p sum of all diagnostic procedures ϫ cost of procedure (National Health Laboratory Services, unpublished data).
• Medication cost p costs of all medications given in hospital + cost of all medications given to take out at discharge + costs of all medications given to take out at review (Dr George Mukhari Hospital, unpublished data).
• Nondrug order cost p sum of (volume ϫ unit cost) of all nondrug orders given during hospital stay (Dr George Mukhari Hospital, unpublished data). When less than the full package volume was given, the costs of all intravenous fluids were calculated for the full package.
• Transportation costs p actual cost of transportation (private or public) to reach Dr George Mukhari Hospital + costs of transportation to visit patient in hospital.
• Previous treatment costs p cost of all previous treatment given for current diarrheal episode.
• Incidental costs p cost of food or other incidental items bought during hospital stay
• Wages lost p number of days of work lost ϫ daily wage.
All data were imported into EpiInfo 2000 [17] for statistical analysis. The mean costs of the rotavirus-positive and the rotavirus-negative or untested patients were compared by Student's t tests (for normally distributed data) and the KruskallWallace test (for nonnormal distributions), with P ! .05 indicating statistical significance, as were the mean costs of the 2004 and 2005 samples. Total costs were converted from South African rands (R) to international dollars (ID) using the exchange rate of 2.671 [18] .
RESULTS
The record review sample comprised 86 patient records, of which 44 had rotavirus test results. Of patients tested for rotavirus, 20 (45%; 23% of total sample) were positive. The sample for the prospective arm comprised 77 patients. Stool samples of 71 (93%) of the prospectively enrolled samples were tested for rotavirus, and 25 (35%; 33% of total sample) were rotavirus positive. The sample description is summarized in Table 1 .
The mean duration of hospital stay for the rotavirus-positive and -negative or untested patients was the same for the 2004 sample ( ). Although the mean duration ‫ע(‬ standard P p .86 deviation [SD]) of hospital stay (2005 sample) for the rotaviruspositive patients ( days) was shorter than that for 5.04 ‫ע‬ 6.1 the rotavirus-negative or untested patients ( days; 6.1 ‫ע‬ 3.9 ), the difference was unlikely to be clinically signifi-P p .042 cant. None of the patients from 2004 died during hospitali- zation, and one of the patients seen in 2005 died before hospital discharge. Facility and professional costs. The facility and professional costs for rotavirus-positive and -negative or untested patients were very similar in the 2004 sample ( ) (Table P 1 .05 2). For the 2005 sample, all costs for the rotavirus-negative or untested sample were higher than those for the rotavirus-positive sample, but only those for hospital stay and total facility use were statistically significant ( ). The total mean facility P ! .05 and professional cost (‫ע‬SD) was for the R6565.00 ‫ע‬ 4870 combined samples, with ∼10% of the cost attributable to professional costs.
Diagnostic and treatment costs. Table 3 shows the mean (‫ע‬SD) costs of diagnostic tests, medications, and nondrug orders. Chemical pathology analyses (urea and electrolyte levels, total protein level, and liver enzyme and glucose levels) made the major contribution to the total diagnostic cost (73%) for both samples. The cost per patient of rotavirus testing was the same for both the 2004 and 2005 samples (R25.40). Because only 51% of the record review sample was tested for rotavirus, the total mean cost (‫ע‬SD) for rotavirus testing (R14.40 ‫ע‬ ) was significantly less than the mean cost of rotavirus 12.67 testing in the prospective enrollment sample ( ) R22.43 ‫ע‬ 8.10 ( ). Radiology costs for chest radiographs contributed P ! .001 minimally to the total diagnostic costs in both samples (2004: ; 2005: ). Because chest radio-R16.57 ‫ע‬ 12.72 R18.63 ‫ע‬ 20.54 graphs were considered to be unrelated to the diagnosis of diarrheal disease, this cost was not included in the calculation of the total diagnostic cost.
Medication costs were calculated for antibiotics, vitamin and mineral supplements, and other medications. Table 3 shows the combined costs for medications given in hospital and to take out at discharge and at follow-up. Antibiotics were prescribed for 67% of the 2004 sample and 52% of the 2005 sample. Although there were no statistically significant differences in the types of antibiotics prescribed between the rotavirus-positive and rotavirus-negative or untested groups ( ) in the P 1 .05 2004 sample, the cost of penicillin and, thus, of antibiotics was significantly higher for the rotavirus-negative or untested patients in the 2005 sample ( ). Intravenous penicillin P p .002 was the most frequently prescribed antibiotic, given to 45% of the combined samples, with a minimum cost of !R1.00 to a maximum of R278.00. Other prescribed antibiotics for the combined sample included gentamicin (23%), cefuroxime (6%), cefotaxime (1%), amikacin (3%) amoxicillin and clavulanic acid (5%), and ceftriaxone (6%). Trimethoprim-sulphamethoxazole was the most frequently prescribed antibiotic to take out.
Vitamin and mineral supplements were given primarily as multivitamin drops (infants) or syrup (children 112 months of age). Very few patients (5 in the combined 2004 and 2005 samples) received single nutrient supplements, including iron, potassium chloride, magnesium sulphate, zinc sulphate, and folate. Vitamin and/or mineral preparations were prescribed for only 28% of the record review sample, with a mean cost (‫ע‬SD) of per patient. There did not appear to R9.00 ‫ע‬ 12.14 be any differences in the types or costs of vitamin and/or mineral prescriptions given to rotavirus-positive and rotavirus-neg- Costs of medications other than antibiotics and nutrient supplements were minimal for all samples. Paracetamol was prescribed for 32% and 27% of record review and prospective enrollment samples during their hospital stay, with a mean cost of 25c and 17c per patient, respectively ( ). P 1 .05 Nondrug orders included oral rehydration mixture (Sorol), intravenous half-strength Darrows with 5% dextrose in water, intravenous normal saline, and intravenous colloid solutions. Sorol was provided as dry powder sachets, made up to 1 L with the addition of water and given to the patient by the caregiver. Recording of the amount of Sorol given to the child was extremely poor. The prescribed amount of Sorol was therefore used to calculate the nondrug order cost. In the record review sample, there was no difference in the mean costs of prescribed Sorol ( ) between the rotavirus-positive and the rotavirus-P 1 .05 negative or untested samples. For the 2005 sample, the only statistically significant difference in mean cost between rotavirus-positive and rotavirus-negative or untested patients was for Sorol given at discharge, which was prescribed for all the rotavirus-positive patients but for only half of the rotavirusnegative or untested patients ( ). Comparison of the P ! .05 mean total costs for nondrug orders between the 2004 and 2005 samples showed no statistically significant differences among the rotavirus-positive, rotavirus-negative or untested, or total samples ( ). P 1 .5 Despite all the mean costs being higher in the prospective enrollment (2005) sample, the difference in final total cost did not reach statistical significance (
). In 2004, the total P 1 .05 cost per patient ranged from R2090 to R24215, with a mean daily cost of R6449. The total cost per patient ranged from R1743 to R39269, with a mean of R7782 in 2005. The facility and professional cost accounted for 92% and 93% of the total costs for the 2004 and 2005 samples, respectively, and diagnostic tests comprised 5% and 4% of the total cost, respectively. Medication and nondrug order costs contributed minimally to the total patient costs (1%-2%).
Direct nonmedical costs. The caregivers of all inpatients enrolled in the prospective sample consented to be interviewed ( ). None of the variables tested showed statistically sign p 77 nificant differences between rotavirus-positive and rotavirusnegative or untested patients. Table 4 summarizes the direct nonmedical (out-of-pocket) expenses incurred. Because Dr George Mukhari Hospital is a tertiary level hospital, most patients (88%) had been referred to the hospital from primary care clinics (39; 57%), other hospitals (10; 15%), or general practitioners (19; 28%). Transportation costs thus included the cost to the first consultation location and from the first consultation location to the hospital.
The highest percentage (46%) of caregivers used taxis to reach the first location of consultation, as did 6 (75%) of those who went directly to Dr George Mukhari Hospital. Private cars were used by 21 caregivers to reach the primary health care center or general practitioner and to go from there to the hospital. Ambulances were used to transport 45% of patients and their caregivers from the clinics or other hospitals (including 2 patients transported from home). The cost of the ambulance was accounted for by the Provincial Government and was therefore not calculated into the transportation cost.
The mean total cost (‫ע‬SD) of transportation from home to the hospital was , with a maximum cost of R9.45 ‫ע‬ R20.61 R150.00 for a caregiver using a private car. Additional transportation costs ( , ) were incurred mean ‫ע‬ SD R51.52 ‫ע‬ 59.78 by caregivers and family members of 17 patients from visiting the child while in the hospital.
The majority of caregivers (82%) sought treatment elsewhere before the current visit (treatment at the referral clinic was not considered to be prior treatment). The highest mean cost of previous treatment was incurred by 42% of caregivers by consultations with traditional healers with a maximum cost of R350.00. General practitioners were consulted by 5 caregivers, the costs ranging from R100.00 to R120.00 per visit. The mean cost (‫ע‬SD) for prior consultations for the whole sample was . Only 15 caregivers (19.5%) had spent money R71.76 ‫ע‬ 89.58 on food during the hospital visit, at a mean cost (‫ע‬SD) of . R21.93 ‫ע‬ 18.03
Indirect costs. Financial losses were difficult to calculate, because only 13 caregivers (17%) were formally employed. Of these, 4 reported that they would lose wages as a result of the child's illness. The remainder stated that wages would not be deducted provided they had proof of their hospital visit.
The child's illness affected all but one carer financially. The majority (70%) met the expenses by cutting spending in other areas, and 20% borrowed money. The mean total out-of-pocket cost to the caregivers for the diarrheal episode was R100.00, with a maximum of R650.00. Previous treatment contributed most to this cost (71%), followed by transportation costs (20%). Other expenses incurred during the illness were minimal.
DISCUSSION
We estimated the mean cost to the hospital per inpatient admission to be R7079 for the combined 2004 and 2005 samples and the mean out-of-pocket cost to the household to be R100. In a similar approach to that of Nelson et al [19] in Hong Kong, the cost of the outpatient visit immediately before hospitalization and the costs of follow-up visits were included in the total facility and professional cost. Thus, the total inpatient costs reflect not only the daily hospital bed cost, but also all facility and professional costs related to the admission. These costs, however, are applicable only to other tertiary South African hospitals and cannot be generalized to all South African public hospitals. The daily facility cost for the 2004-2005 financial year of primary level hospitals was approximately onethird (R369) and of secondary level hospitals less than onehalf (R470) that of tertiary level hospitals [16] . In addition, because most primary and secondary level hospitals do not employ permanent specialist pediatricians, professional costs would be lower. Facility and professional costs would thus be approximately one-third of the calculated cost for primary level facilities (R1987-R2485) and one-half for secondary level facilities (R2980-R3728).
Patient stool samples were not routinely tested for rotavirus during the study period. Those tested were done so as part of the MRC Diarrheal Pathogens Unit Surveillance program, and thus, the incidence of rotavirus infection in the record review sample was similar to that found in the 2003, 2004, and 2005 surveillance studies (17%, 21%, and 25%, respectively) (J Dewar, personal communication). The higher prevalence of 33% rotavirus-positive specimens found in the prospective enrollment sample was probably because the study covered the peak rotavirus season and a concerted effort was made to obtain stool specimens from enrolled patients. Thus, the cost of rotavirus testing is likely to be closer to the 2005 than to the 2004 cost.
The major contributing factor to the cost of diarrheal disease management was the combined facility and professional cost, which was driven by the duration of hospitalization. The mean durations of hospital stay of 4.6 and 5.7 days for the record review and prospective enrollment samples, respectively, are similar to the mean duration of stay for patients with diarrheal disease treated in the Department of Paediatrics and Child Health (4-6 days) (Department of Paediatrics and Child Health, Medunsa/Ga-Rankuwa Hospital, unpublished data) and to hospital stays for diarrheal disease reported from Asia [19] [20] [21] but longer than those reported from the United States [9] and Europe [22] .
Diagnostic, medicine, and nondrug order costs contributed ∼7% of the total management cost and did not differ between years or between rotavirus-positive and rotavirus-negative or untested samples. This is in agreement with the findings of Fischer et al [21] , who found that these cost contributed ∼11% of the total hospital cost in Vietnam.
Of note, in the 2005 sample, the cost of antibiotics was higher for the rotavirus-negative or untested patients than for the rotavirus-positive patients. This difference could be attributed to the higher mean cost of intravenous penicillin administered to the rotavirus-negative or untested patients ( ) and P ! .005 the higher prevalence of comorbidities among the negative or untested groups. Of concern, in both 2004 and 2005, there was a large discrepancy between the percentage of patients prescribed antibiotics (66%) and the percentage of microbiological tests ordered. This suggests that over-prescription of antibiotics could have occurred, increasing hospitalization costs unnecessarily.
Problems were encountered particularly in the record review sample with the calculation of volumes of both intravenous and oral solutions administered, because records of intake did not correspond to the prescriptions. During the prospective enrollment arm of the study, the research assistant monitored the administration of both the intravenous and oral solutions, thus improving the accuracy of recording. For standardization, all calculations were based on the prescribed rates and volumes, with the assumption that the prescribed volumes would have been given. With regard to oral rehydration, despite there being a standard protocol based on age and weight for the prescription of oral rehydration solutions [23] , specific prescriptions were not given. Instead, Sorol was simply ordered as the number of sachets (usually 2-3 per admission and 2 sachets to take home at discharge).
Out-of-pocket costs incurred by the caregivers were remarkably similar to those reported in Uzbekistan [24] , Vietnam [21] , Europe [22] , and the United States [8] . In South Africa, children !6 years of age are treated free of charge at state facilities; however, prior treatment by either general practitioners or traditional healers contributed 70% of the cost to caregivers. The second largest cost to families was that for transportation (20%). Also as reported from Uzbekistan [25] , caregivers covered their expenses by cutting expenses from elsewhere or receiving loans from relatives or friends. The estimated out-of-pocket expense of R100.00 could represent у10% of the income of the community [25] and, because only 17% of the caregivers were formally employed, could have a substantial negative impact on the household.
As was the case with hospital costs, care must be taken in generalizing these out-of-pocket expenses to other South Af-rican populations. The caregivers interviewed were from areas close to the hospital, with easy access to transportation and relatively short distances to health care facilities. Thus, although our costs may be representative of out-of-pocket expenses for communities in urban areas, they may underestimate the costs to households in peri-urban and rural communities, where distances to health care facilities are great, transportation costs are high, and costs of caring for a sick child are greater, in terms of both time and money. In addition, because household incomes are lower in rural and peri-urban than in urban areas [25] , the cost of diarrheal disease is likely to have a greater negative impact on households.
It is clear that the facility and professional costs made the largest contribution to the total inpatient cost-a finding that agrees with other published studies [21, 25] . Our results showed that the costs associated with rotavirus diarrhea were similar to if not lower than diarrhea from other causes. Our cost estimation for diarrheal disease is considerably higher than costs reported from other developing countries. For example, Fischer et al [21] reported a mean hospital cost of US$369 from Vietnam, and a mean hospital cost of US$69 was reported from Uzbekistan [24] . In contrast, the mean hospital costs of admissions for rotaviral disease varied from US$1748 to US$2145 in Hong Kong [25] , from i1220 to i1484 in Europe [22] , and from US$3354 to US$3836 in the United States [8] . Because South Africa has a mixed economy, it is not surprising that our estimated hospital cost is closer to those of developed rather than developing countries.
The present study was not designed to determine the cost effectiveness of a rotavirus vaccine. It is, nonetheless, useful to consider the cost implications of a rotavirus vaccine. On the basis of the incidence of 33% of diarrheal admissions attributable to rotavirus infection found in the prospective arm of our study, the published efficacy of 93% [8, 9] , and assuming universal coverage, rotavirus vaccination could prevent an estimated 248 (30%) of hospital admissions for severe diarrhea. This would represent a cost savings of ∼R1.76 million to Dr George Mukhari Hospital. To determine cost effectiveness, these savings would have to be balanced against the costs associated with the rotavirus vaccine and would require the application of accurate national costs from all levels of care into economic models, such as has been done in Hong Kong [26] and the United States [8] .
Although a rotavirus vaccine could reduce the burden of diarrheal disease by an estimated 30%, it is clear that diarrhea due to other etiologies accounts for the major burden and economic cost of diarrheal disease in South Africa. It is therefore imperative that measures for reducing the incidence and severity of diarrheal disease caused by other pathogens are strengthened. Furthermore, the use of a tertiary facility doubles or triples the cost of hospitalization for diarrheal disease. Therefore, steps need to be taken to equip primary and secondary level facilities to manage diarrheal disease to obviate the need for these patients to be treated in a tertiary level facility.
